Sweden's Equalis invests in CellaVision's new product for external quality assurance of laboratory tests in hematology
(Thomson Reuters ONE) -
CellaVision has signed an agreement with Equalis, the Swedish provider of
external quality assessment for clinical laboratory tests. Equalis has chosen to
invest in CellaVision's new proficiency testing program for the identification
of cells in blood and other body fluids, CellaVision® Proficiency Software. The
order comprises a license for 350 users.
During the year, the product will be introduced in Equalis' quality assurance
scheme for Swedish clinical laboratories in Hematology.
"With CellaVision Proficiency Software, we reach out easily to our scheme
participants in hematology and can offer them a digital quality control tool
that creates conditions for increased knowledge and more standardized test
results, says Gunnar Nordin, Managing Director and Chief Medical Officer at
Equalis. "One of the great benefits of the program, in addition to allowing us
to easily distribute, monitor and follow up tests on-line, is that participants
get instant feedback on their performance in form of valuable statistics. The
program is both a testing tool and a source to increase knowledge."
The program is web-based and located on a cloud server, allowing it to be run
from any computer without the need for software installation. The fact that the
program is on-line also means that the quality organization can more easily
collect and create a customized database of interesting patient cases. The
program uses digital images of white and red cells in blood and other body
fluids.
"When designing the program, our goal was to make proficiency testing more
manageable and efficient for EQA organizations, as well as individual
laboratories. When compared to the traditional testing method which use blood
smears on glass slides, this software is efficient, user friendly and allows all
participants to view and identify the same cells. This greatly simplifies
administration, performance and monitoring of the test, as well as creating
conditions for faster analysis and more accurate reporting", said Emma Jacobsén,
Product Manager at CellaVision.
CellaVision Proficiency Software is sold as an annual license directly by
CellaVision. The program is available in two versions, Enterprise Edition for
external quality assessment organizations with up to 2000 users, and
Professional Edition for laboratories and universities with 10-100 users. The
Professional Edition includes a customized web portal. More information can be
found at www.cellavision-proficiency.com.
For more information, please contact:
Emma Jacobsén, Product Manager, CellaVision AB
Tel: +46 708 13 73 22. E-mail: emma.jacobsen(at)cellavision.com
About Equalis
Equalis is an accredited provider of external quality assessment for clinical
laboratory investigations based in Sweden. The company is owned by the Swedish
Association of Local Authorities and Regions, the Swedish Society of Medicine
and the Swedish Institute of Biomedical Laboratory Science. Equalis is working
to improve the quality of the investigations used as a basis for diagnosis and
treatment within health care. The objective is increased patient safety. As an
accredited organizer of external quality assessment Equalis provides a hundred
different quality assurance schemes in laboratory medicine and in imaging and
functional medicine. Equalis also works with education, standardization and
quality improvement activities. Read more at www.equalis.se/en.
About CellaVision
CellaVision is an innovative, global medical technology company that develops
and sells its own leading systems for routine analysis of blood and other body
fluids in health care services. The products rationalize manual laboratory work,
and secure and support effective workflows and skills development within and
between hospitals. The company has leading-edge expertise in image analysis,
artificial intelligence and automated microscopy. In most countries sales are
via global partners. Products are sold directly in the Nordic countries and via
subsidiaries in the US, Canada and Japan. In 2012 sales were SEK 170 million and
sales continue to increase, with a growth target of at least 15 % per year over
an economic cycle. CellaVision's registered office is in Lund, Sweden. The share
is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at
www.cellavision.com.
Photo: CellaVision Proficiency Software:
http://hugin.info/132164/R/1699170/560972.jpg
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: CellaVision AB via Thomson Reuters ONE
[HUG#1699170]
Unternehmensinformation / Kurzprofil:
Datum: 07.05.2013 - 11:01 Uhr
Sprache: Deutsch
News-ID 256784
Anzahl Zeichen: 5401
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 234 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sweden's Equalis invests in CellaVision's new product for external quality assurance of laboratory tests in hematology"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
